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An aim of the ECDC point prevalence survey (PPS) in 
European Union/European Economic Area acute care 
hospitals was to acquire standardised healthcare-
associated infections (HAI) data. We analysed one of 
the most common HAIs in the ECDC PPS, healthcare-
associated pneumonia (HAP). Standardised HAI case 
definitions were provided and countries were advised 
to recruit nationally representative subsets of hos-
pitals. We calculated 95% confidence intervals (CIs) 
around prevalence estimates and adjusted for cluster-
ing at hospital level. Of 231,459 patients in the survey, 
2,902 (1.3%; 95% CI: 1.2–1.3) fulfilled the case defini-
tion for a HAP. HAPs were most frequent in intensive 
care units (8.1%; 95% CI: 7.4–8.9) and among patients 
intubated on the day of the survey (15%; 95% CI: 14–17; 
n = 737 with HAP). The most frequently reported micro-
organism was Pseudomonas aeruginosa (17% of 1,403 
isolates), followed by  Staphylococcus aureus (12%) 
and Klebsiella spp. (12%). Antimicrobial resistance was 
common among isolated microorganisms. The most 
frequently prescribed antimicrobial group was peni-
cillins, including combinations with beta-lactamase 
inhibitors. HAPs occur regularly among intubated 
and non-intubated patients, with marked differences 
between medical specialities. HAPs remain a priority 
for preventive interventions, including surveillance. 
Our data provide a reference for future prevalence of 
HAPs at various settings.
Introduction
  Healthcare-associated pneumonia (HAP) causes 
a considerable burden of disease in the European 
Union/European Economic Area (EU/EEA) [1], which 
is at least partially preventable [2]. Surveillance of 
healthcare-associated infections (HAIs) can contribute 
to prevention by increasing awareness and by provid-
ing data for the prioritisation of interventions and for 
their subsequent evaluation [3].
Point prevalence surveys (PPSs) are a surveillance 
methodology well-suited to HAI surveillance. They are 
easier to conduct and much less costly than incidence 
surveillance of HAIs, even though they have drawbacks 
in terms of assessing causality and the overrepresen-
tation of patients with long hospital stays [4]. Several 
PPSs that assessed HAP prevalence have been con-
ducted in Europe and North America [5-17]; however, 
their methods differed. For example, some PPSs did 
not specify the number of intubated patients, a group 
known to be at increased risk for HAP, while others 
reported cases of lower respiratory tract infections 
rather than pneumonia, limiting comparability across 
PPSs.
The European Centre for Disease Prevention and Control 
(ECDC) PPS of HAIs and antimicrobial use in EU/EEA 
acute care hospitals from 2011–12 applied a standard-
ised methodology for the surveillance of HAIs, includ-
ing HAP, throughout the EU, as well as in Croatia (EU 
Member State since 1 July 2013), Iceland and Norway, 
referred to herein as the EU/EEA for brevity. This very 
large study included data on HAIs, as well as on micro-
biological results and antimicrobial use [18]. Previous 
publications include a report on the overall analyses of 
the ECDC PPS [18] and a report on the analysis of data 
from paediatric patients [19], though HAP were not ana-
lysed in detail in these reports. We present the results 
of an analysis focusing on HAP in EU/EEA acute care 
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Pneumonia
Two or more serial chest X-rays or CT-scans with a suggestive image of pneumonia for patients with underlying cardiac or pulmonary disease. In patients 
without underlying cardiac or pulmonary disease, one definitive chest X-ray or CT-scan is sufficient
AND at least one of the following symptoms
• fever > 38 °C with no other cause;
• leukopenia (< 4,000 WBC/mm3) or leucocytosis (≥ 12,000 WBC/mm3);
AND at least one of the following (or at least two if clinical pneumonia only = PN4 and PN5):
• new onset of purulent sputum, or change in character of sputum (colour, odour, quantity, consistency);
• cough or dyspnea or tachypnea;
• suggestive auscultation (rales or bronchial breath sounds), ronchi, wheezing;
• worsening gas exchange (e.g. O2 desaturation or increased oxygen requirements or increased ventilation demand).
Microbiological characterisation according to the used diagnostic method
(i) Bacteriological diagnostic test performed by:
• Positive quantitative culture from minimally contaminated LRT specimen (PN1):
 − BAL with a threshold of > 104 CFU/mL or ≥ 5% of BAL obtained cells contain intracellular bacteria on direct microscopic exam (classified on the 
diagnostic category BAL);
 − protected brush (PB Wimberley) with a threshold of > 103 CFU/mL;
 − distal protected aspirate (DPA) with a threshold of > 103 CFU/mL.
• Positive quantitative culture from possibly contaminated LRT specimen (PN2):
 − Quantitative culture of LRT specimen (e.g. endotracheal aspirate) with a threshold of 106 CFU/mL.
(ii) Alternative microbiology methods (PN3):
• positive blood culture not related to another source of infection;
• positive growth in culture of pleural fluid;
• pleural or pulmonary abscess with positive needle aspiration;
• histologic pulmonary exam shows evidence of pneumonia;
• positive exams for pneumonia with virus or particular germs (Legionella spp., Aspergillus spp., mycobacteria, mycoplasma, Pneumocystis carinii):
 − positive detection of viral antigen or antibody from respiratory secretions (by e.g. enzyme immunoassay , fluorescent-antibody-to-membrane-antigen, 
shell vial assay, PCR tests);
 − positive direct exam or positive culture from bronchial secretions or tissue;
 − seroconversion (e.g. for influenza viruses, Legionella spp., Chlamydia spp.);
 − detection of antigens in urine (Legionella spp.).
(iii) Others:
• positive sputum culture or non-quantitative LRT specimen culture (PN4);
• no positive microbiology (PN5).
Neonatal pneumonia
Respiratory compromise;
AND
New infiltrate, consolidation or pleural effusion on chest X-ray;
AND at least four of:
• temperature > 38 °C or < 36.5 °C or temperature instability;
• tachycardia or bradycardia;
• tachypnoea or apnoea;
• dyspnoea;
• increased respiratory secretions;
• new onset of purulent sputum;
• isolation of a pathogen from respiratory secretions;
• C-reactive protein > 2.0 mg/dL;
• I/T ratio > 0.2.
Intubation-associated pneumonia
Pneumonia is defined as intubation-associated if an invasive respiratory device was present (even intermittently) within the 48 hours preceding the 
onset of infection.
BAL: broncho-alveolar lavage; CFU: colony-forming units; CT: computed tomography; ECDC: European Centre for Disease Prevention and Control; I/T: 
immature to total neutrophil ratio; LRT: lower respiratory tract; PN: pneumonia; WBC: white blood cells.
aEuropean Union countries, plus Croatia (EU Member State since 1 July 2013), Iceland and Norway.
Box
Case definitions for pneumonia, neonatal pneumonia and intubation-associated pneumonia, ECDC point prevalence survey 
in acute care hospitals, European Union/European Economic Areaa, 2011–2012
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Figure 
Prevalence of healthcare-associated pneumonia, ECDC point prevalence survey in acute care hospitals, European Union/
European Economic Areaa, 2011–2012 (n = 231,459 patients)
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HAP prevalence
ECDC: European Centre for Disease Prevention and Control; HAP: healthcare-associated pneumonia; UK: United Kingdom.
aEuropean Union countries, plus Croatia (EU Member State since 1 July 2013), Iceland and Norway.
bCountries with poor or very poor representation of their national sample of participating hospitals, as defined in the ECDC report [18].
Countries are ranked from highest to lowest observed prevalence of HAP, according to the ECDC point prevalence survey case definition, with 
95% confidence intervals. The value of each national prevalence is shown in parenthesis adjacent to each country name. The vertical line 
indicates the overall prevalence of HAP, i.e. 1.25%.
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Table 1
Characteristics of healthcare-associated pneumonia cases and non-cases collected in the ‘standard’ surveillance option, 
ECDC point prevalence survey in acute care hospitals, European Union/European Economic Areaa 2011–2012 (n = 215,537)
Characteristics
HAPb 
 
N
Totalb 
 
N
HAP prevalence
Odds ratio (95% CI)
% of all patients (95% CI) p value
Total 2,748 215,537
Age
     < 1 month 61 7,592 0.8 (0.5–1.2)
  
 
  
 
< 0.0001
1.5 (1.1–2.0)
    1–11 months 67 5,135 1.3 (1.0–1.8) 2.1 (1.6–2.8)
    1–44 years 276 46,838 0.6 (0.5–0.7) Reference
    45–74 years 1,188 88,726 1.3 (1.2–1.5) 2.4 (2.1–2.7)
    75–84 years 776 43,665 1.8 (1.6–2.0) 3.2 (2.8–3.7)
     ≥ 85 years 377 23,319 1.6 (1.4–1.8) 3.1 (2.6–3.6)
Sex
    Female 1,024 113,517 0.9 (0.8–1.0)
< 0.0001
0.6 (0.5–0.8)
    Male 1,717 101,137 1.7 (1.6–1.8) Reference
McCabe score
    Nonfatal 991 142,925 0.7 (0.6–0.8)   
 
< 0.0001
Reference
    Ultimately fatal 855 34,780 2.5 (2.2–2.7) 3.6 (3.3–4.0)
    Rapidly fatal 485 11,275 4.3 (3.9–4.8) 6.7 (6.0–7.6)
Intubated on survey date
    Yes 737c 4,906 15 (14–17)
< 0.0001
18 (17–20)
    No 1,999c 20,9774 1.0 (0.9–1.0) Reference
Length of stay until HAP or until survey dates (days)d
     ≤ 3 399 71,000 0.6 (0.5–0.6)   
 
  
 
< 0.0001
Reference
    4–7 560 57,327 1.0 (0.9–1.1) 1.7 (1.5–1.9)
    8–14 494 41,740 1.2 (1.1–1.3) 2.0 (1.8–2.3)
     ≥ 15 772 43,911 1.8 (1.6–1.9) 3.1 (2.7–3.5)
Hospital type
    Primary care 291 31,401 0.9 (0.8–1.1)   
 
  
 
< 0.0001
Reference
    Secondary care 845 75,275 1.1 (1.0–1.3) 1.3 (1.0–1.6)
    Tertiary care 1,383 85,363 1.6 (1.5–1.8) 1.8 (1.5–2.3)
    Specialised 121 12,573 1.0 (0.7–1.4) 0.8 (0.6–1.2)
Hospital size (number of beds)
     < 200 202 21,200 1.0 (0.8–1.2)   
 
  
 
< 0.0001
Reference
    200–399 561 50,069 1.1 (1.0–1.3) 1.2 (0.9–1.4)
    400–649 644 55,746 1.2 (1.0–1.3) 1.2 (1.0–1.5)
     ≥ 650 1,341 88,522 1.5 (1.3–1.7) 1.6 (1.3–2.1)
Speciality
    Geriatrics 101 8,982 1.1 (0.9–1.5)
  
 
  
 
  
 
  
 
< 0.0001
1.0 (0.8–1.2)
    Gynaecology/Obstetrics 12 16,493 0.07 (0.04–0.13) 0.1 (0.0–0.1)
    Intensive care unit 853 10,504 8.1 (7.4–8.9) 7.1 (6.5–7.8)
    Medical 1,138 88,745 1.3 (1.1–1.4) Reference
    Mixed 3 782 0.4 (0.1–1.2) 0.3 (0.1–1.1)
    Other 13 1,160 1.1 (0.6–2.2) 1.0 (0.6–1.7)
    Paediatrics 60 12,037 0.5 (0.3–0.7) 0.4 (0.3–0.5)
    Psychiatrics 9 8,226 0.1 (0.1–0.2) 0.1 (0.0–0.2)
    Rehabilitation 28 3,068 0.9 (0.6–1.5) 0.7 (0.5–1.0)
    Surgery 530 65,370 0.8 (0.7–0.9) 0.6 (0.5–0.7)
CI: confidence interval; ECDC: European Centre for Disease Prevention and Control; HAP: healthcare associated pneumonia; IQR: interquartile 
range.
aEuropean Union countries, plus Croatia (EU Member State since 1 July 2013), Iceland and Norway.
bColumns may not tally to the total due to missing data.
cEighty percent (587/737) of patients with intubation on the survey date and 15% (303/1,999) of patients without incubation on the survey date 
were classified as intubation-associated pneumonia.
dExcluding patients with HAP at admission.
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hospitals that participated in the ECDC PPS with the 
aim of providing a reference for the prevalence of HAPs 
at various settings, which can aid the interpretation of 
locally collected surveillance data and guide preven-
tive interventions.
Methods
Study design
The ECDC PPS aimed to measure the prevalence of HAIs 
Table 2
Microorganisms isolated in healthcare-associated pneumonia cases according to association with intubation, time of onset 
and diagnostic category, ECDC point prevalence survey in acute care hospitals, European Union/European Economic Areaa, 
2011–2012 (n = 1,403 isolates)
Microorganism
All 
HAP 
cases
Intubation-associated Time of onsetb Diagnostic category
Yes No/Unknown ≤ 4 days 5–7 days ≥ 8 days PN1–PN3
c PN4c
n % n % n % n % n % n % n % n %
Total 1,403 100 827 100 576 100 199 100 184 100 718 100 648 100 725 100
Gram-positive cocci 265 19 126 15 139 24 53 27 42 23 115 16 124 19 132 18
  Staphylococcus aureus 168 12 79 10 89 15 32 16 24 13 76 11 77 12 86 12
  Coagulase-negative staphylococci 22 2 9 1 13 2 3 2 3 2 11 2 12 2 8 1
  Streptococcus spp. 35 2 13 2 22 4 14 7 9 5 9 1 12 2 22 3
  Enterococcus spp. 31 2 18 2 13 2 1 1 5 3 17 2 19 3 12 2
  Other Gram-positive cocci 9 1 7 1 2 0 3 2 1 1 2 0 4 1 4 1
Gram-negative cocci 18 1 5 1 13 2 4 2 3 2 10 1 6 1 12 2
Gram-positive bacilli 6 0 4 0 2 0 0 0 1 1 2 0 4 1 2 0
Enterobacteriaceae 454 32 275 33 179 31 69 35 59 32 225 31 186 29 254 35
  Citrobacter spp. 12 1 8 1 4 1 1 1 2 1 3 0 7 1 5 1
  Enterobacter spp. 71 5 43 5 28 5 13 7 8 4 39 5 20 3 47 6
  Escherichia coli 120 9 68 8 52 9 16 8 19 10 58 8 45 7 72 10
  Klebsiella spp. 164 12 102 12 62 11 28 14 15 8 81 11 68 10 91 13
  Proteus spp. 33 2 22 3 11 2 4 2 4 2 15 2 21 3 11 2
  Serratia spp. 37 3 24 3 13 2 4 2 10 5 18 3 15 2 21 3
  Other Enterobacteriaceae 17 1 8 1 9 2 3 2 1 1 11 2 10 2 7 1
Non-fermenting Gram-negative bacteria 4,444 32 302 37 142 25 39 20 51 28 264 37 222 34 217 30
  Acinetobacter spp. 136 10 106 13 30 5 7 4 21 11 81 11 63 10 72 10
  Pseudomonas aeruginosa 244 17 154 19 90 16 29 15 22 12 141 20 129 20 112 15
  Stenotrophomonas maltophilia 47 3 30 4 17 3 3 2 4 2 29 4 19 3 27 4
  Other Pseudomonadaceae 17 1 12 1 5 1 0 0 4 2 13 2 11 2 6 1
Other Gram-negative bacteria 64 5 31 4 33 6 20 10 15 8 18 3 26 4 37 5
  Haemophilus spp. 51 4 28 3 23 4 18 9 15 8 13 2 18 3 32 4
  Legionella spp. 3 0 0 0 3 1 1 1 0 0 0 0 3 0 0 0
  Other Gram-negative bacteria 10 1 3 0 7 1 1 1 0 0 5 1 5 1 5 1
Anaerobic bacilli 1 0 0 0 1 0 0 0 0 0 1 0 0 0 1 0
  Bacteroides spp. 1 0 0 0 1 0 0 0 0 0 1 0 0 0 1 0
Other bacteria 5 0 2 0 3 1 0 0 0 0 3 0 4 1 1 0
Fungi and parasites 143 10 81 10 62 11 14 7 13 7 77 11 73 11 69 10
  Candida spp. 99 7 64 8 35 6 13 7 10 5 51 7 49 8 49 7
  Aspergillus spp. 33 2 11 1 22 4 0 0 3 2 21 3 18 3 15 2
  Other fungi and parasites 11 1 6 1 5 1 1 1 0 0 5 1 6 1 5 1
Viruses 3 0 1 0 2 0 0 0 0 0 3 0 3 0 0 0
ECDC: European Centre for Disease Prevention and Control; HAP: healthcare-associated pneumonia; LRT: lower respiratory track; spp.: 
species.
aEuropean Union countries, plus Croatia (EU Member State since 1 July 2013), Iceland and Norway.
bExcluding 302 isolates due to HAP at admission or due to missing dates.
cPN1–PN3: bacteriologic diagnostic test for pneumonia performed by positive quantitative culture from minimally (PN1) or possibly (PN2) 
contaminated LRT specimen, or by alternative microbiological methods (PN3) (see Box); PN4: positive sputum culture or non-quantitative 
LRT specimen culture (see Box).
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in acute care hospitals with a similar precision in each 
EU/EEA country. ECDC recommended that countries 
select hospitals to participate by clustered random 
sampling, if possible. All acute care hospitals were eli-
gible. Prevalence data on HAIs, antimicrobial use and 
selected risk factors were collected by trained data col-
lectors on one single day per ward during the 2011–12 
survey period (generally outside the winter period of 
December to March and the summer holiday period 
of July to August, with peaks of data collection from 
September to November 2011 and May to June 2012) 
[18]. Hospitals chose to collect data either at patient 
level (‘standard’ option) or in partially aggregated form 
(‘light’ option). Prior to the ECDC PPS, case definitions 
were developed through international consultations 
and were tested in a pilot study [20].
To assess the severity of each patient’s underlying 
disease (standard option only), study staff allocated a 
McCabe score, classified as either non-fatal, ultimately 
fatal (expected survival between 1 and 5 years) or rap-
idly fatal (expected survival less than 1 year) [21].
Case definition
The ECDC PPS case definition for HAP arises from the 
ECDC PPS definition of a pneumonia and a HAI [22]:
A pneumonia (Box) was defined as:
‘Active’ on the day of the survey when: signs and symp-
toms were present on the date of the survey; OR signs 
and symptoms were no longer present but the patient 
was still receiving treatment for an infection on the 
date of the survey;
‘healthcare-associated’ (i.e. HAP) when: the onset of 
the signs and symptoms was on Day 3 of the current 
admission or later (with Day 1 being the day of admis-
sion); OR the signs and symptoms were present on 
admission or became apparent before Day 3, and the 
patient had been discharged from an acute care hospi-
tal less than two days before admission.
HAP was stratified into five disease codes, from PN1 
to PN5, corresponding to different degrees of microbio-
logical evidence for non-neonatal pneumonia and into 
‘Neo-Pneu’ for neonatal pneumonia according to the 
case definitions shown in the Box.
All analyses used the ECDC PPS definition for HAP, 
which differs from the definitions used in other pub-
lications that differentiate hospital- and healthcare-
associated pneumonia [22,23].
Statistical analyses
Prevalence was calculated by dividing the number of 
patients with HAP by all patients in the hospital at the 
time of the survey. We included data from both the 
‘light’ and the ‘standard’ option for the calculation of 
the overall and country-specific prevalence estimates. 
We only included hospitals using the ‘standard’ option 
for the risk factor analysis. We adjusted the calculation 
of confidence intervals (CIs) around the HAP preva-
lence to account for the clustered study design (i.e. the 
design effect) using the Stata survey command (svy) 
and specifying the option ‘singleunit (scaled)’ in case 
there were strata with only one cluster. Pearson chi-
squared tests were also adjusted for the design effect 
using the survey command, and were used to assess 
associations of covariates with the HAP prevalence. 
Odds ratios (ORs) were calculated by mixed logistic 
regression modelling, including a random offset at hos-
pital level to adjust for clustering.
Categories for age, hospital size and medical speciality 
were chosen to match the main ECDC report [18]. The 
time between the most recent admission to the sur-
veyed hospital and the onset of symptoms was divided 
into three categories (≤  4 days, 4–7  days, ≥  8 days), 
partially as done previously [24] and partially to reflect 
the relatively late onset of disease seen in this dataset. 
We used Anatomic Therapeutic Chemical classification 
system (ATC) 3 and 4 categories (https://www.whocc.
no/atc_ddd_index) for the analysis of antibiotic use.
All analyses were conducted in Stata 14.1 (College 
Station, Texas, United States (US)).
Ethical approval was at the discretion of each national 
public health and government body. Anonymised 
patient- and institution-level data was shared with 
ECDC and collaborating partners for this analysis.
Results
Healthcare-associated pneumonia prevalence
A total of 231,459 patients from 947 hospitals in 30 EU/
EEA countries were included in the dataset. HAP was 
present in 2,902 patients resulting in a prevalence of 
1.3% (95% CI: 1.2–1.3%) among hospitalised patients 
in acute care hospitals in Europe. The HAP prevalence 
varied between 0.6% (95% CI: 0.2–1.4%) in Latvia 
and 3.7% (95% CI: 1.0–12.3%) in Iceland (Pearson chi-
squared adjusted for clustering: p value <  0.0001 over 
all countries) (Figure).
 
For 2,838 (98%) of the HAP cases, information on 
whether intubation had been present before the onset 
of HAP was available. Of these, 947 (33%) had an intu-
bation-associated pneumonia (IAP), while the remain-
ing 1,891 (67%) cases had not been intubated before 
the onset of their HAP.
The majority (93%, n  =  880) of hospitals used the 
‘standard’ patient-based surveillance option. They 
included 215,537 patients, for whom an in-depth analy-
sis is possible. Among these, we found HAP to be sig-
nificantly associated with older age, male sex, higher 
McCabe score, intubation and prolonged hospital stay. 
HAP was most frequent among intensive care unit (ICU) 
patients, in tertiary care hospitals and in large hospi-
tals (Table 1).
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Laboratory data
Five hundred and sixteen (18%) HAP cases were 
defined as laboratory-confirmed based on the case 
definition code (PN1–PN3); 2,258 (78%) cases were 
non-laboratory confirmed (PN4 or PN5) and 64 (2%) 
were classified as neonatal pneumonia. The classifica-
tion was missing for 64 (2%) HAP cases. The propor-
tion of laboratory-confirmed cases (PN1–PN3) varied 
between 55% in Norway and 1% in Cyprus; it was higher 
in ICU patients than in non-ICU patients (32% vs 12%, 
p < 0.001).
One thousand one hundred and sixty-six (40%) 
patients with HAP had one or more microbiological 
result reported to ECDC (including all case definition 
codes except PN5). Of these, 103 (9%) patients had 
sterile samples. Of the remaining 1,063 patients, 478 
(45%) were classified as PN1–PN3, 558 (52%) as PN4, 
16 (2%) as neonatal pneumonia and 11 (1%) as unspeci-
fied. From the 1,166 patients, 1,403 isolates of microor-
ganisms were identified. The isolated microorganisms 
were mostly bacteria (90%; 1,257 isolates), and were 
rarely fungi or parasites (10%; 143 isolates) or viruses 
(< 1%; 3 isolates). The most frequently reported microor-
ganism was  Pseudomonas aeruginosa  (17%), followed 
by  Staphylococcus aureus (12%) and  Klebsiella  spp. 
(12%) (Table 2).
The distribution of microorganisms differed signifi-
cantly between IAP and non-IAP HAP cases (p < 0.001). 
Gram-positive cocci were isolated less frequently from 
IAP cases than non-IAP cases (15% vs 24%) and non-
fermenting Gram-negative bacteria were isolated more 
frequently (40% vs 30%). The largest differences were 
for Acinetobacterspp. (13% vs 5%) and S. aureus  (10% 
vs 15%) (Table 2).
Similarly, the distribution of microorganisms differed 
by time of onset of HAP (p < 0.001). Gram-positive cocci 
were isolated less frequently in HAP with late onset 
(27% at ≤ 4 days, 23% at 5–7 days and 16% at ≥ 8 days). 
Gram-negative bacteria were more frequent in HAP 
with late onset (30%, 36% and 39%, respectively). The 
largest differences between ≤  4 vs ≥  8 days of onset 
per microorganism were seen for  Acinetobacter  spp. 
(4% vs 11%) and  Haemophilus  spp. (9% vs 2%), and 
differences generally did not exceed 10% (Table 2).
There was little difference in the distribution of micro-
organisms from patients fulfilling the case definitions 
PN1–PN3 (obtained specimens less likely to be contam-
inated) vs those in category PN4 (obtained specimens 
more likely to be contaminated) (p = 0.07) (Table 2).
Antimicrobial susceptibility testing results for selected 
microorganism–antimicrobial combinations were avail-
able for 841 isolates, mostly showing a high proportion 
of non-susceptibility. For example, 91 (81%) of 112 iso-
lates of Acinetobacter spp. were non-susceptible to car-
bapenems and 73 (47%) of 157 S. aureus isolates were 
resistant to meticillin (i.e. MRSA). Carbapenem-non-
susceptibility was common among P. aeruginosa (81 of 
204 isolates; 40%) (Table 3).
There were some differences in the proportion of antimi-
crobial resistance / non-susceptibility between isolates 
from IAP and non-IAP HAP cases, as well as associations 
between these proportions and the time of onset of 
infection. Significant differences by time of onset were 
identified for meticillin resistance among S. aureus, for 
carbapenem-non-susceptibility among  Klebsiella  spp. 
and  P. aeruginosa, and for non-susceptibility to third-
generation cephalosporins among Enterobacteriaceae, 
as shown in Table 3. Finally, carbapenem-non-suscep-
tibility among  Acinetobacter  spp. was more frequent 
among IAP than non-IAP HAP cases (Table 3).
Antimicrobial use
Of the 2,902 patients with HAP, 2,471 (85%) were 
receiving 3,453 antimicrobials as therapy for HAP; one 
patient with HAP was receiving five different antimicro-
bials. An additional 379 (13%) HAP cases were receiv-
ing antimicrobials for reasons other than HAP.
Most of the antimicrobials prescribed to treat HAP were 
penicillins (30% of 3,453 antimicrobials) including 
combinations of penicillins with beta-lactamase inhibi-
tors (24%), extended-spectrum penicillins without 
anti-pseudomonal activity (3%) and beta-lactamase 
inhibitors (2%). The second most commonly prescribed 
group of antimicrobials was other beta-lactam antibac-
terials (24%) including carbapenems (12%), third-gen-
eration cephalosporins (8%) and second-generation 
cephalosporins (3%). The third most commonly pre-
scribed group of antimicrobials was the unspecific 
group of ‘other antibacterials’ (14%), including gly-
copeptide antibacterials (6%), polymyxins (4%) and 
imidazole derivatives (3%). Other prescribed antimi-
crobials were fluoroquinolones (10%), aminoglycosides 
(5%); antimycotics for systemic use (5%), macrolides, 
lincosamides and streptogramins (5%), tetracyclines 
(2%), and sulphonamides and trimethoprim (2%). 
Antimicrobials for the treatment of tuberculosis, intes-
tinal anti-infectives, combinations of antibacterials 
and amphenicols were reported in less than 1% of HAP 
cases.
To obtain an overview of empiric antimicrobial therapy 
choices for HAP, we performed a sub-analysis of anti-
biotic regimens for HAP that were given to patients 
without microbiologically confirmed HAP (‘PN5’) and 
stratified them between IAP and HAP without known 
intubation before symptom onset (non-IAP HAP). We 
also excluded those receiving antibiotic treatment for 
other reasons than a HAP. There were 1,203 patients 
included in this sub-analysis; 220 had an IAP and 983 
had a non-IAP HAP. Among patients with an IAP, the 
most frequently prescribed single antimicrobial group 
was the combination of penicillins, including beta-
lactamase inhibitors (24%), followed by carbapen-
ems (9%), third-generation cephalosporins (7%) and 
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second-generation cephalosporins (6%). An additional 
35% of the patients received combinations of antimi-
crobial groups. Among patients with a non-IAP HAP, the 
most frequently prescribed single antimicrobial group 
was the combination of penicillins, including beta-lac-
tamase inhibitors (35%), followed by fluoroquinolones 
(8%), third-generation cephalosporins (6%) and car-
bapenems (5%). The combination of several antimicro-
bial groups was prescribed for 28% of the patients.
In addition, 874 patients who did not meet the case 
definition for a HAP were reported as receiving antimi-
crobial treatment for HAP according to the treating phy-
sician. Of these, 533 (61%) were in the United Kingdom 
(UK) and Ireland.
Discussion
The ECDC PPS showed that on the day of the survey, 
one in 80 hospitalised patients in EU/EEA countries 
is diagnosed with a HAP (prevalence: 1.3%; 95% CI: 
1.2–1.3), with a nearly 7 times higher prevalence in 
ICUs (8.1%; 95% CI: 7.4–8.9) and marked differences 
between other specialities. As expected, patients with 
longer hospital stay, older patients and men had a 
higher prevalence of HAP.
Approximately one in six intubated patients had a HAP 
on the day of the ECDC PPS (15%; 95% CI: 14–17); how-
ever, two thirds of all patients with a HAP had not been 
intubated in the 48 hours before the onset of their HAP. 
Additionally, 15% of patients with a HAP who were intu-
bated on the day of the survey were intubated after 
the onset of the HAP. This confirms that while intuba-
tion remains the main risk factor for HAP, HAPs also 
occur in non-intubated patients [25]. Surveillance of all 
HAPs, including non-intubated HAP cases, is required 
to assess the full burden of HAPs. Prevention of HAP 
should also take into account non-intubated patients.
The number of hospitalised patients developing a HAP 
during hospital stay in EU/EEA countries is high. HAPs 
are associated with a high case fatality and long-term 
adverse clinical outcomes. With about 269 disability-
adjusted life years (DALYs) per 100,000 population, 
they represent the largest fraction of the overall bur-
den of disease of HAIs and they contribute a higher 
burden of disease for the EU/EEA than any of the other 
32 communicable diseases under surveillance at EU/
EEA level and studied in [1,26]. ECDC estimates that 
there are 702,315 (95 %CI: 664,764–744,419) cases of 
HAP each year in EU/EEA countries, resulting in an esti-
mated 26,972 (CI: 21,859–32,541) attributable deaths 
[1].
The HAP prevalence estimated here for the EU/EEA is 
generally within the prevalences estimated in other 
studies. Most recent PPSs from Europe and North 
America reported a prevalence of HAP or healthcare-
associated lower respiratory tract infection of around 
1% [5-12,17] and up to 2.8% [13-17], which is generally 
consistent with data from the ECDC PPS; however, the 
HAP prevalence was slightly lower (0.9%) in a large PPS 
in the US [9]. This difference is unlikely to be explained 
by different case definitions, as they have been shown 
to be comparable [27], but may be linked to longer 
hospital stays in the ECDC PPS (median time between 
admission and survey date: 6 days) [18] than the US 
PPS (median time between admission and survey date: 
3 days), which would increase the risk of developing 
and chances of detecting a HAP.
A relatively high number (n = 874) of patients, many of 
them in the UK and Ireland, suffered a HAP according 
to the clinicians’ judgement, but did not fulfil the ECDC 
PPS case definition. This could either indicate a prob-
lem with the implementation of the rather complex HAP 
case definition used in the ECDC PPS, or it may sim-
ply be due to differences in the surveillance and clini-
cal case definitions, as they have different objectives. 
Clinical case definitions are likely to be more sensi-
tive, in order to avoid undertreatment. Further studies 
would be needed to determine the true cause for this 
difference in the number of HAP cases.
Microbiological results were present for only 40% of 
the cases, which is much lower than in the US PPS (87 
/ 110 (79%) HAP) [9], which may indicate differences in 
diagnostic practices or study procedures. However, the 
three most common microorganisms (Staphylococcus 
aureus, Klebsiella  spp.,  P. aeruginosa) were the same 
in the two PPSs. Furthermore, some of the identi-
fied microorganisms are rare causes of pneumonia 
(e.g. coagulase negative  S. aureus,  Enterococcus  spp. 
and Candida spp.) and isolation of these microorganisms 
may reflect contamination or colonisation rather than 
infection. Nevertheless, since a definite decision of 
the underlying aetiology of HAP was not possible, we 
decided to present these in the results section.
As expected for HAP, a large proportion of the identified 
microorganisms were antimicrobial-resistant. Some 
of the multiresistant pathogens have a high potential 
for further spread and tend to cause nosocomial out-
breaks. By design, PPSs over-represent patients with 
long hospital stays, who are also at increased risk of 
infections with resistant microorganisms. In addition, 
in the ECDC PPS, antimicrobial resistance data were 
more frequently available for patients with longer hos-
pital stays. Despite these possible biases, the high 
proportion of carbapenem-non-susceptibility (81% 
of Acinetobacter spp., 40% of P. aeruginosa and 11% of 
Enterobacteriaceae) is worrying. Common treatments, 
such as with a combination of penicillins, including 
beta-lactamase inhibitors, may be ineffective against 
such carbapenem-non-susceptible microorganisms, 
limiting treatment options and making the use of last-
line antimicrobials for empirical treatment necessary.
Even though we found significant differences in the 
distribution of microorganisms between IAP and non-
IAP HAP cases and an association between their dis-
tribution and time of onset, these differences were 
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relatively small, only rarely exceeding 10%. In contrast, 
larger differences were seen in non-susceptibility for 
selected antimicrobials, between late- and early-onset 
HAP cases or between IAP and non-IAP HAP cases. 
However, these data should be interpreted with caution 
because of the PPS design, which means an over-rep-
resentation of patients with longer hospital stays and 
an over-representation of patients with HAIs, because 
they require longer treatment.
In addition, the specific design of PPSs does not make 
them suited to identify causal pathways. As with other 
surveillance activities, PPSs are limited in the number 
of collected variables to assess risk factors. For exam-
ple, co-morbidities are commonly assessed by the 
McCabe score, which is a highly subjective tool. A PPS 
is therefore limited in its usefulness to produce con-
crete recommendations for specific prevention strate-
gies, but it remains an important item in the toolbox for 
the prevention of HAPs and other HAIs [3].
Inter-country comparisons of the prevalence of HAP 
from this study should be made with caution. Firstly, 
the ECDC PPS was not powered for the outcome of only 
HAP, but for all HAIs. Secondly, many countries were 
not able to include a representative sample of acute 
care hospitals. Thirdly, despite training sessions for 
data collectors, there may have been differences in the 
implementation of the ECDC PPS protocol in participat-
ing countries and acute care hospitals, which may have 
influenced the sensitivity and specificity of ECDC PPS 
results. Indeed, four countries conducted validation 
studies on the same day as their ECDC PPS, comparing 
data collection by primary data collectors to a national, 
external team. The country estimates for the sensitiv-
ity of HAI detection differed greatly (range: 58%–94%). 
Some differences in the estimated national HAP preva-
lences may have been due to national differences in 
the consequences for reporting HAIs, such as a current 
or historical risk to the reporter [18].
Nevertheless, the ECDC PPS provided the first ‘snap-
shot’ of HAIs across EU/EEA countries, confirming that 
HAIs are a major health threat for acute care hospi-
tals in the region. The ECDC PPS also collected data 
on the structures and process indicators of infection 
prevention and control, thereby highlighting interven-
tion options for local and national policymakers [18]. 
Additionally, a repeat of the ECDC PPS in 2017–18 will 
provide an update on HAPs in Europe. In conclusion, 
the ECDC PPS confirms that HAP is a frequent HAI, 
especially among intubated patients but also com-
monly among non-intubated patients, requiring contin-
ued prevention efforts. Our data provide a reference as 
basis for future prevalence of HAPs at various settings.
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